Arcutis Biotherapeutics, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-08-05. Between them they name 3 people, with 2 appointments and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Departing: L. Todd Edwards, effective 2026-08-21
On July 31, 2026, L. Todd Edwards notified Arcutis Biotherapeutics, Inc. (the "Company") of his decision to resign as chief commercial officer of the Company, effective as of August 21, 2026.
Appointed: Robert Lisicki
The Company has commenced a search for a permanent chief commercial officer and has appointed Robert Lisicki as interim executive vice president, starting August 17, 2026, and as interim chief commercial officer, effective upon Mr. Edwards' departure from the Company on August 21, 2026.
Appointed: Christopher Peetz, Director
On July 15, 2026, the Board of Directors (the "Board") of Arcutis Biotherapeutics, Inc. (the "Company") increased the authorized number of directors on the Board from nine to ten directors and appointed Mr. Christopher Peetz as a new member of the Board.
Find people with the same kind of experience as the Director at Arcutis Biotherapeutics, Inc., with the record behind each one.
Find candidates like Director at Arcutis Biotherapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Arcutis Biotherapeutics, Inc. is in the news or changes leadership.
Get an alert when Arcutis Biotherapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Arcutis Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.